About: Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
Creator	Cho, Byung-Sik Cho, Seok-Goo Da-Bin, & Eom, Ki-Seong Jeon, Young-Woo Kim, Dong-Wook Kim, Hee-Je Kim, Yoo-Jin Lee, Jong Lee, Seok Lee, Sung-Eun Lim, Ji-Young Min, Chang-Ki Park, Sung Ryu, Woo, Tae Yoon, Jae-Ho
Source	Medline; PMC
abstract	The aim of this study was to explore the predictive implications of the composition of immune cell populations prior to lenalidomide plus high-dose dexamethasone (Len-Dex) initiation for the occurrence of infections. We prospectively examined immune cell populations in peripheral blood taken at baseline of lenalidomide plus low-dose dexamethasone (Len-dex) therapy and reviewed clinical and microbiology records in 90 patients with refractory/relapsed multiple myeloma (RRMM). Risk factors for infection were analyzed using logistic regression. During a median of 11 cycles of Len-dex treatment, 52 (57.8%) patients experienced at least 1 infection episode. Of a total of 92 episodes of infection, 58 (63%) episodes were clinically defined, 29 (31.5%) episodes were microbiologically defined, and 5 (5.4%) episodes were fever of unknown origin. Severe episodes were more frequently observed during the first 3 cycles. After adjusting for risk factors for infection based on univariate analyses, multivariate analyses showed that lower Hb (< 10 g/dL) was a clinically independent factor associated with occurrence of infections. Lower frequency (P = 0.044) and absolute count (P = 0.014) of circulating CD3(+)CD4(+)CD161(+) cells prior to Len-dex treatment were also associated with the occurrence of infection, especially during the first 3 cycles of Len-dex therapy. In addition to several clinical predictive factors, we found that CD3(+)CD4(+)CD161(+) cells may provide additional information for predicting the occurrence of infection in the early period of Len-dex therapy. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00277-018-3401-y) contains supplementary material, which is available to authorized users.
has issue date	2018-06-25(xsd:dateTime)
bibo:doi	10.1007/s00277-018-3401-y
bibo:pmid	29938309
has license	no-cc
sha1sum (hex)	dfc6ff77e8a97e14ed02dba9db3eb068ed82ec95
schema:url	https://doi.org/10.1007/s00277-018-3401-y
resource representing a document's title	Low frequency of CD3(+)CD4(+)CD161(+) T cells correlates with the occurrence of infections in refractory/relapsed multiple myeloma patients receiving lenalidomide plus low-dose dexamethasone treatment
has PubMed Central identifier	PMC7079859
has PubMed identifier	29938309
schema:publication	Ann Hematol
resource representing a document's body	covid:dfc6ff77e8a97e14ed02dba9db3eb068ed82ec95#body_text
is schema:about of	named entity 'RECEIVING' named entity 'LOW-DOSE' named entity 'RISK FACTORS' named entity 'LOW-DOSE' named entity 'EPISODE' named entity 'CLINICAL' named entity 'REFRACTORY' named entity 'ANALYZED' named entity 'INFECTION' named entity 'INFECTIONS' named entity 'FREQUENCY' named entity 'PATIENTS' named entity 'LENALIDOMIDE' named entity 'LOWER' named entity '28P' named entity 'RECORDS' named entity 'LOGISTIC REGRESSION' named entity 'COUNT' named entity '044' named entity 'INITIATION' named entity 'PREDICTIVE' named entity 'BASELINE' named entity 'STUDY' named entity 'TOTAL' named entity 'IMMUNE CELL' named entity 'USING' named entity 'ABSOLUTE' named entity 'PREDICTING' named entity 'AIM' named entity 'CELLS' named entity 'ADDITION' named entity 'PRIOR TO' named entity 'ASSOCIATED WITH' named entity 'ADDITIONAL INFORMATION' named entity 'COMPOSITION' named entity 'REFRACTORY' named entity 'PERIOD' named entity 'OBSERVED' named entity 'TREATMENT' named entity 'FEVER OF UNKNOWN ORIGIN' named entity '2857' named entity 'CD4' named entity 'LENALIDOMIDE' named entity 'OCCURRENCE' named entity 'PROVIDE' named entity 'EXPERIENCED' named entity 'EPISODES' named entity 'ADJUSTING' named entity 'FACTOR' named entity 'EARLY' named entity 'TAKEN' named entity 'POPULATIONS' named entity 'LEN' named entity 'BASED' named entity 'DEXAMETHASONE' named entity 'CIRCULATING' named entity 'CD161' named entity 'CD3' named entity 'CD4' named entity 'DEXAMETHASONE' named entity 'T CELLS' named entity 'PATIENTS' named entity 'MULTIPLE MYELOMA' named entity 'MULTIPLE MYELOMA' named entity 'THERAPY'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software